Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 41.53% | 40.36% | 19.52% | 17.61% | 81.54% |
| Total Depreciation and Amortization | -58.69% | -57.84% | -42.99% | -41.62% | -14.76% |
| Total Amortization of Deferred Charges | 18.59% | 20.98% | -- | -- | 13.35% |
| Total Other Non-Cash Items | -149.04% | -150.03% | 102.78% | 102.85% | -97.88% |
| Change in Net Operating Assets | 95.83% | 95.75% | 98.49% | 98.45% | -40.89% |
| Cash from Operations | 58.94% | 58.12% | 66.40% | 65.60% | 38.13% |
| Capital Expenditure | -- | -- | -- | -- | -3,506.90% |
| Sale of Property, Plant, and Equipment | -42.86% | -41.84% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 100.00% | -243.24% | -251.65% | -101.24% |
| Cash from Investing | 102.66% | 102.70% | -112.09% | -112.37% | -109.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -58.49% | -58.49% | 9.78% | 9.78% | 86.82% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,360.00% | 4,360.00% | 22,680.00% | 22,680.00% | -99.51% |
| Cash from Financing | -91.54% | -91.37% | 2,209.01% | 2,258.32% | 170.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -199.06% | -201.05% | 89.74% | 89.50% | 210.15% |